See What HealthDay Can Do For You
Contact Us

Rotavirus Vaccination Tied to Lower Risk for T1DM in Children

No association seen for partial vaccination and incidence of type 1 diabetes


FRIDAY, June 14, 2019 (HealthDay News) -- Completion of full rotavirus vaccination appears to be associated with a reduction in the risk of type 1 diabetes in children, according to a study published online June 13 in Scientific Reports.

Mary A.M. Rogers, Ph.D., from the University of Michigan in Ann Arbor, and colleagues utilized data from a nationwide health insurer for 1,474,535 infants in the United States from 2001 to 2017 to examine the correlation between rotavirus vaccination and incidence of type 1 diabetes.

The researchers found that compared with no rotavirus vaccination, completion of the rotavirus vaccine series correlated with a 33 percent reduction in the risk for type 1 diabetes. The risk for type 1 diabetes was 37 percent lower with completion of the pentavalent vaccine series. No correlation was noted for partial vaccination (incompletion of the series) with the incidence of type 1 diabetes. Compared with unvaccinated children, in the 60-day period after vaccination, there was a 31 percent reduction in hospitalizations. Overall, a 3.4 percent decrease in the incidence rates of type 1 diabetes was seen annually in children aged 0 to 4 years in the United States from 2006 to 2017, correlating with introduction of the vaccine in 2006.

"While additional studies are needed to explore this association in more detail, it is possible that rotavirus vaccination may be the first practical measure that could play a role in the prevention of this disease," the authors write.

Abstract/Full Text

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.